On Tuesday, the United States health officials gave the final clearance to kid-size Pfizer coronavirus dose. This milestone opens a major expansion of the vaccination campaign of the country to children as young as five. The Food and Drug Administration (FDA) previously approved the vaccine doses for children ages five to eleven – shots just a third of the amount given to adults and teens.

However, the Centers for Disease Control and Prevention (CDC) officially authorizes who should receive FDA-cleared vaccines. CDC director Dr. Rochelle Walensky made the announcement a few hours after an advisory panel consistently decided Pfizer doses should be available for the twenty-eight million youngsters in that age group. The announcement marks the first opportunity for Americans under age twelve to receive the vaccination shots of any vaccine brand.

CDC accepted the Advisory Committee on Immunization Practices’ (ACIP) recommendation that children ages 5–11 be vaccinated against #COVID19.

The COVID-19 vaccine authorized for this group is over 90% effective at preventing COVID-19.

More: https://t.co/cX2X5nMns7

— CDC (@CDCgov) November 3, 2021

In a statement, Walensky encouraged the American parents with questions to talk to their pediatrician, local pharmacist, or school nurse to learn more about the effectiveness of vaccines and the importance of getting their children inoculated. Earlier in the day, she said that as the risk of severe illness and death is lower in young kids than adults, it is real – and coronavirus has had a profound mental health, educational and social impact on youngsters, including flaring inequalities in learning.

A Turning Point for America

Joe Biden, the President of the United States, called the decision from the health officials “a turning point.” Biden stated that it would allow American parents to end months of anxiety worrying about their children and cut the extent to which kids spread the COVID-19 virus to others. Further, he added that it is a significant step ahead for the U.S. nation in the fight to defeat the deadly virus.

Furthermore, the American Academy of Pediatrics greeted the decision as its team got ready to inject shots into little arms, which the CDC said could start as early as possible. The five to eleven-year-old kids will receive two low vaccine shots, three weeks apart, of the Pfizer/BioNTech – the same schedule as everyone else, but with a smaller needle. Over the weekend, Pfizer started shipping millions of the pediatric doses to states, pharmacies, and doctor’s offices – in orange caps, unlike purple-capped vials for the adult vaccine.

Several parents insisted on vaccine protection for youngsters so they can restart normal childhood activities without risking their own health – or fear bringing COVID-19 home to a weaker family member. However, advisers to the CDC panel said they spot several parents who also have questions and maybe fearful of the coronavirus vaccine because of widespread misinformation.

Advisory panel members said they want American parents to ask about the vaccine doses and understand that they are far better than gambling that their kid will escape a severe infection. As for safety purposes, over one hundred and six million Americans safely received two shots of full-strength Pfizer vaccine doses – including over seven million twelve- to fifteen-year-old children.

Is a kid-size vaccine being effective at preventing symptomatic Coronavirus?

According to the government statistics, there have been over eighty-three hundred COVID-19-related hospitalizations of children ages five to eleven in the United States, about a third requiring ICU. Moreover, the CDC recorded around ninety-four deaths in that age group, with further reports under investigation. Pfizer’s study of about 2268 young Americans found the children-size vaccine is almost ninety-one percent effective at preventing symptomatic coronavirus infection – based on sixteen diagnoses among children administered dummy shots compared to only three who received the real vaccination shots.

In addition, the FDA examined more kids, a total of thirty-one hundred kids who received the vaccination, and concluded that the doses were safe. The younger kids faced mild or similar reactions – such as fever, achiness, or sore arms – than young adults or teens get after larger shots. However, that study was not big enough to spot any rare side effects in extreme conditions, like heart inflammation that usually occurs after the second full-strength shot, mostly in teen boys and young men.

Finally, the regulators decided the vaccination benefits overshadow the possibility that younger children getting a smaller shot also might experience that mild risk. Last week, the advisers of FDA struggled with whether every young kid needed a vaccine. Young children hospitalized with coronavirus are more possibly to have high-risk conditions like diabetes and obesity. However, otherwise, healthy kids can get seriously ill, too, and the advisers to the CDC finally endorsed the doses for all of them – even children who previously recovered from a spell of coronavirus.

What about Younger Kids?

CDC officials considered that for every five hundred thousand youngsters inoculated, between eighteen thousand and fifty-eight thousand coronavirus cases – and between eighty and two hundred and twenty-six hospitalizations – in that age group would prevent infection, depending on the trajectory of the outbreak. However, CDC officials also noted that coronavirus caused more deaths in this age group than other diseases like chickenpox did before kids vaccinated in routine against them.

Pfizer is testing vaccine shots for preschoolers and babies and expects statistics across the end year. Additionally, the similarity made Moderna coronavirus vaccine also being studied with young kids. However, the FDA still has not cleared its use in teens, and the firm is delaying its application for younger kids pending that review. Some nations started using other coronavirus vaccines in kids under twelve, including China, which started shots for three-year-old.

Read Also: FDA Delays Decision on Moderna Vaccine EUA for Adolescents